OncoVista Innovative Therapies (OncoVista Innovative Therapies) FCF Margin % : 0.00% (As of Sep. 2015)

View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OncoVista Innovative Therapies's Free Cash Flow for the three months ended in Sep. 2015 was $-0.03 Mil. OncoVista Innovative Therapies's Revenue for the three months ended in Sep. 2015 was $0.00 Mil. Therefore, OncoVista Innovative Therapies's FCF Margin % for the quarter that ended in Sep. 2015 was 0.00%.

As of today, OncoVista Innovative Therapies's current FCF Yield % is 0.00%.

The historical rank and industry rank for OncoVista Innovative Therapies's FCF Margin % or its related term are showing as below:

OVIT's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.09
* Ranked among companies with meaningful FCF Margin % only.

OncoVista Innovative Therapies FCF Margin % Historical Data

The historical data trend for OncoVista Innovative Therapies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies FCF Margin % Chart

OncoVista Innovative Therapies Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

FCF Margin %

Get a 7-Day Free Trial

OncoVista Innovative Therapies Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of OncoVista Innovative Therapies's FCF Margin %

For the Biotechnology subindustry, OncoVista Innovative Therapies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's FCF Margin % falls into.

OncoVista Innovative Therapies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OncoVista Innovative Therapies's FCF Margin for the fiscal year that ended in Dec. 2014 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2014 )	/	Revenue (A: Dec. 2014 )
	=	-0.232	/	0
	=	%

OncoVista Innovative Therapies's FCF Margin for the quarter that ended in Sep. 2015 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2015 )	/	Revenue (Q: Sep. 2015 )
	=	-0.027	/	0
	=	%

OncoVista Innovative Therapies FCF Margin % Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245

Website

http://www.oncovista.com

OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.

Executives

Alexander Ruckdaeschel	director	123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal	director	C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson	10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd	10 percent owner	411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines